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Accurate prediction of B-cell epitopes has remained a
challenging task in computational immunology despite
several decades of research. Only 10% of the known B-
cell epitopes are estimated to be continuous, yet they are
often the targets of predictors because a solved tertiary
structure is not required and they are integral to the
development of peptide vaccines and engineering thera-
peutic proteins. In this article, we present COBEpro, a
novel two-step system for predicting continuous B-cell
epitopes. COBEpro is capable of assigning epitopic pro-
pensity scores to both standalone peptide fragments and
residues within an antigen sequence. COBEpro first uses
a support vector machine to make predictions on short
peptide fragments within the query antigen sequence and
then calculates an epitopic propensity score for each
residue based on the fragment predictions. Secondary
structure and solvent accessibility information (either
predicted or exact) can be incorporated to improve per-
formance. COBEpro achieved a cross-validated area
under the curve (AUC) of the receiver operating charac-
teristic up to 0.829 on the fragment epitopic propensity
scoring task and an AUC up to 0.628 on the residue epi-
topic propensity scoring task. COBEpro is incorporated
into the SCRATCH prediction suite at http://scratch.pro-
teomics.ics.uci.edu.
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Introduction
B-cell epitopes are the portions of antigens that are recog-
nized by the variable regions of B-cell antibodies.
Researchers can use knowledge about epitopes to design
diagnostic tests (Schellekens et al., 2000), develop synthetic
vaccines (Tam and Lu, 1989; Hughes and Gilleland, 1995)
and engineer therapeutic proteins (Chirino et al., 2004). In
contrast to T-cell epitope prediction, B-cell epitope predic-
tion has yet to reach a high level of accuracy and remains a
very challenging task in computational immunology.
Historically, researchers have differentiated continuous
epitopes (epitopes that consist of a linear sequence of resi-
dues) from discontinuous epitopes (epitopes that consist of a
non-linear collection of residues). It is estimated that only
10% of the B-cell epitopes are continuous (Pellequer et al.,
1991). However, van Regenmortel (van Regenmortel, 2006)
pointed out that many discontinuous epitopes consist of
several groups of linearly continuous residues and that con-
tinuous epitopes have a tertiary structure. Thus, it is worth-
while to develop continuous epitope predictors since systems
trained only on continuous epitopes could be useful to ident-
ify both continuous and discontinuous epitopes.
Initial attempts at predicting epitopes involved propensity
scales combined with various local averaging techniques
(Hopp and Woods, 1981; Parker et al., 1986; Pellequer et al.,
1991; Pellequer et al., 1993). On small datasets, these
methods appeared to be quite useful. However, Blythe and
Flower (Blythe and Flower, 2005) showed that on a larger
dataset, no simple propensity scale and averaging technique
could do much better than random.
Recently, there have been two general approaches for con-
tinuous epitope prediction. One approach is to assign an anti-
genic propensity score to each residue in the query protein.
This approach is followed by Larsen et al. (Larsen et al.,
2006) and So¨llner and Mayer (So¨llner and Mayer, 2006).
Another approach to epitope prediction is to classify
sequence fragments as an epitope or a non-epitope. This
approach is followed by Saha and Raghava (Saha and
Raghava, 2006), Chen et al. (Chen et al., 2007) and
El-Manzalawy et al. (El-Manzalawy et al., 2008).
In this article, we present COBEpro, a two-step system for
the prediction of continuous B-cell epitopes. In the first step,
COBEpro assigns a fragment epitopic propensity score to
protein sequence fragments using a support vector machine
(SVM) with a unique set of input features. While most pre-
vious methods use an artificially fixed length fragment,
COBEpro is capable of using sequence fragments of any
length. In addition, COBEpro can incorporate predicted or true
secondary structure and solvent accessibility into the SVM. In
the second step, COBEpro calculates an epitopic propensity
score for each residue based on the SVM scores of the peptide
fragments in the antigen sequence. In this article, we show
that COBEpro achieves high levels of performance on several
publicly available datasets relative to previously published
methods. Moreover, COBEpro addresses both the problem of
distinguishing epitope peptide fragments from non-epitope
peptide fragments and the problem of assigning an epitopic
propensity score to residues within an antigen sequence. In
addition to benchmarking COBEpro on several common con-
tinuous B-cell epitope datasets, we also benchmark COBEpro
on a discontinuous B-cell epitope dataset and make blind pre-
dictions for the top 10 antigens recently identified in the
pathogen Francisella tularensis (Sundaresh et al., 2007).
Methods
Datasets and preparation
In this article, we used several different datasets to train and
benchmark COBEpro. These datasets were derived from
several different previously published sources: BciPep (Saha
et al., 2005), Pellequer (Pellequer et al., 1993) and HIV
(Korber et al., 2003). The BciPep datasets consist of epitope/
non-epitope sequence fragments. The Pellequer and HIV
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datasets consist of whole antigen proteins annotated with
precise epitope boundaries.
The BciPep database was originally curated by Saha et al.
(Saha et al., 2005) and subsequently used for deriving data-
sets and training predictors by Saha and Raghava (Saha and
Raghava, 2006), Chen et al. (Chen et al., 2007) and
El-Manzalawy et al. (El-Manzalawy et al., 2008). The
dataset curated in Chen et al. (Chen et al., 2007) consists of
872 epitope sequence fragments and an equal number of
assumed non-epitope fragments randomly selected from the
SWISS-PROT database. In this article, we refer to the frag-
ment dataset curated by Chen et al. as ChenFrag. Although
the epitopes in the BciPep database are of varying length,
Chen et al. applied a truncation-and-extension method to
create fragments 20 residues in length. Additionally, no
attempt was made by Chen et al. to remove possible homo-
logous antigen sequences.
The redundancy-reduced dataset curated by El-Manzalawy
et al. (El-Manzalawy et al., 2008) consists of 701 epitope
sequence fragments and an equal number of assumed
non-epitope fragments randomly selected from the
SWISS-PROT database. In this article, we refer to the frag-
ment dataset curated by El-Manzalawy et al. as BCPREDFrag.
The truncation-and-extension method was also applied by
El-Manzalawy et al. to curate the BCPREDFrag dataset.
Additionally, El-Manzalawy et al. reduced redundancy in the
BCPREDFrag dataset at an 80% sequence identity threshold.
One concern with the method of randomly selecting
non-epitope fragments from the SWISS-PROT database used
by Chen et al. in the creation of the ChenFrag dataset and by
El-Manzalawy et al. in the creation of the BCPREDFrag
dataset, is that the predictors could learn to discern antigen
sequence from non-antigen sequence as opposed to epitope
fragment/non-epitope fragment classification. We therefore
curated four additional epitope/non-epitope fragment datasets
to evaluate COBEpro’s binary classification performance
using the HIV and Pellequer databases.
The HIV database was originally curated by Korber et al.
(Korber et al., 2003) and a training dataset was subsequently
curated by Larsen et al. (Larsen et al., 2006). This dataset
consists of 10 antigenic proteins and 103 different epitope
fragments. Approximately, 38% of the residues in this
dataset are annotated as belonging to at least one epitope.
The Pellequer database was originally curated by Pellequer
et al. (Pellequer et al., 1993) and a training dataset was sub-
sequently curated by Larsen et al. (Larsen et al., 2006). This
dataset consists of 14 antigens and 83 different epitope frag-
ments. Approximately 34% of the residues in this dataset are
annotated as belonging to at least one epitope.
From these whole sequence datasets, we extracted both
fixed length and variable length fragments. We randomly
selected non-epitope fragments from the non-epitope anno-
tated regions of the antigen sequences. This is in contrast to
the method used by Chen et al. (Chen et al., 2007) and
El-Manzalawy et al. (El-Manzalawy et al., 2008) of ran-
domly selecting non-epitope fragments from SWISS-PROT.
We were able to select non-epitope fragments from antigens
in the datasets because the proteins in the datasets were well
studied and it was likely that most of the epitopes have been
annotated. Our motivation for selecting non-epitope frag-
ments from the same sequence, as opposed to selecting them
randomly from SWISS-PROT, was to ensure that we were
evaluating COBEpro’s ability to discern epitope from
non-epitope fragments, rather than antigen from non-antigen.
For each epitope fragment in the variable length fragment
datasets, PellFragVL and HIVFragVL, 10 non-epitope frag-
ments of the same length were selected. Non-epitope frag-
ments were defined as any peptide fragment not overlapping
with any annotated epitopes. The non-epitope fragments
were randomly selected from the same antigen as the corre-
sponding epitope fragment.
In addition to the variable length fragment datasets, we
curated two fixed length fragment datasets for the HIV and
Pellequer datasets, HIVFragFL and PellFragFL. Based on
results from Chen et al. (Chen et al., 2007) and El-Manzalawy
et al. (El-Manzalawy et al., 2008), we used a fixed length of 20
residues. For each epitope in the HIV and Pellequer datasets
that is less than 20 residues in length, we added the epitope frag-
ment padded on each side as symmetrically as possible with
neighboring residues to the fragment dataset. For each epitope
in the HIV and Pellequer datasets greater than 20 residues in
length, we added all 20 residue fragments within the epitope to
the fragment dataset. For each positive epitope fragment within
the fragment datasets, we added 10 non-epitope fragments, ran-
domly selected from the same antigen sequence, 20 residues in
length not overlapping with any annotated epitopes.
With the availability of the entire antigenic protein
sequence in the HIV and Pellequer datasets, we were able to
predict the secondary structure and relative solvent accessibil-
ity using the SSpro and ACCpro predictors from the
SCRATCH protein structure prediction suite (Pollastri et al.,
2002a, 2002b; Cheng et al., 2005). These predictors achieve
accuracy levels of about 79 and 77%, respectively. Secondary
structure propensity scales and solvent accessibility scales
have been previously used for epitope prediction (Pellequer
et al., 1991; Alix, 1999; Odorico and Pellequer, 2003), but
the propensity scales are far less accurate than SSpro and
ACCpro. For each of the four fragment datasets derived from
the HIV and Pellequer datasets, we curated an additional
dataset augmented with the predicted protein structural
features. These datasets are named HIVFragFLstruct,
HIVFragVLstruct, PellFragFLstruct and PellFragVLstruct.
To benchmark COBEpro’s ability to assign residue epito-
pic propensity scores, we curated two whole sequence data-
sets, PellWholestruct and HIVWholestruct. These datasets
include secondary structure and solvent accessibility predic-
tions. In these datasets, residues within annotated epitopes
were considered epitopic and residues not within any anno-
tated epitopes were considered non-epitopic.
In addition to the various continuous B-cell epitope data-
sets, we benchmarked COBEpro on the discontinuous B-cell
epitope dataset used by Discotope (Haste Andersen et al.,
2006) and BEpro (Sweredoski and Baldi, 2008) (formerly
known as PEPITO). In evaluating COBEpro on this dataset,
we assumed that the tertiary structure is unknown and the sec-
ondary structure and relative solvent accessibility were pre-
dicted from the sequence alone. We also made blind
predictions for the top 10 antigens recently identified in the
pathogen F. tularensis (Sundaresh et al., 2007). This pathogen
causes tularemia, which is a highly virulent and lethal disease.
Fragment epitopic propensity score predictor
COBEpro uses a SVM, as implemented by svmlight
(Joachims, 1999), to assign an epitopic propensity score to
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peptide fragments. The input to the SVM for each peptide
fragment is a vector of similarities to the positive epitope
fragments in the training library. Several similarity measures
were considered, but the total number of identical substrings
was found to be most effective. This similarity measure is
the number of amino acids present in both sequences plus
the number of amino acid dimers present in both sequences
plus the number of amino acid trimers present in both
sequences and so on. The length of the input vector to the
SVM is dependent on the number of positive epitope frag-
ments in the training library. For example, if ‘ABACD’ were
the peptide fragment to be classified and the positive epi-
topes in the training library were ‘ABAD’, ‘BADD’ and
‘ABAB’, then the input to the SVM would be [6, 4, 4] (the
number of identical substrings between the query peptide
and the first positive epitope fragment is 6 (‘A’, ‘B’, ‘D’,
‘AB’, ‘BA’, ‘ABA’), the number of identical substrings
between the query peptide and the second positive epitope
fragment is 4 (‘A’, ‘B’, ‘D’, ‘BA’) and the number of identi-
cal substrings between the query peptide and the third posi-
tive epitope fragment is 4 (‘A’, ‘B’, ‘AB’, ‘BA’)). The same
similarity metric is used for comparing the secondary struc-
ture and solvent accessibility of the peptide fragments using
the respective three-letter secondary structure alphabet (‘H’,
‘E’, ‘C’) and the two-letter relative solvent accessibility
alphabet (‘E’, ‘B’).
We also explored including the similarity scores of the
non-epitope fragments in the training library when calculat-
ing the input vector, but found that the predictor’s perform-
ance actually decreased. It is suspected that the decrease in
performance comes from the different feature space created
within the SVM. With our novel set of inputs, COBEpro can
make predictions for fragments of different lengths and
COBEpro can include secondary structure and solvent acces-
sibility by using three input values for each epitope in the
training library (one for sequence similarity, one for second-
ary structure similarity and one for solvent accessibility
similarity).
For the evaluation of COBEpro on the ChenFrag and
BCPREDFrag datasets, we used a 10-fold cross validation
scheme, where 8 of the folds were used in the training set,
1-fold was used for tuning parameters in the SVM such as
the kernel type (e.g. linear or Gaussian) and kernel para-
meters (e.g. the width s of the Gaussian kernel), and the final
fold was used for evaluation. The default value for the regu-
larization parameter was used for all training. Other settings
were tried, but they did not improve performance.
For the evaluation of COBEpro on the HIV and Pellequer
fragment datasets, we alternated using one of the datasets for
training the SVM and the other for testing. With the avail-
ability of the secondary structure and solvent accessibility
predictions for the HIV and Pellequer datasets, we explored
how their incorporation affects COBEpro’s performance. In
evaluating these two datasets, we used the optimal par-
ameters found in evaluating the ChenFrag dataset.
Residue epitopic propensity score predictor
COBEpro uses a novel method for combining the fragment
epitopic propensity scores to produce an epitopic propensity
score for each residue. COBEpro first obtains the epitopic
propensity score of every possible peptide fragment between
5 and 18 residues in length within the query protein. We
selected the range of 5–18 residues because 95% of the
epitope fragments in our datasets are in this range.
The second step in COBEpro is to combine these fragment
predictions into a single score for each residue. Several
schemes for combining the predictions were explored in the
course of benchmarking our prediction. One simple scheme
would be to sum the raw SVM scores of each peptide frag-
ment overlapping with a given residue. Another possible
scheme would be to assume the highest scoring fragments
are epitopes. In this scheme, a residue would get a positive
‘vote’ for each epitope fragment containing the residue. A
third scheme would assume the lowest scoring fragments are
non-epitopes and a residue would get a negative ‘vote’ for
each non-epitope fragment containing the residue. In the
course of benchmarking COBEpro, we found that combining
the most and least likely peptide fragments worked well and
using the top 5% and bottom 5% scoring fragments yielded
the optimal performance. In this scheme, the positive and
negative votes are summed for each residue (Fig. 1).
Performance measures
To evaluate COBEpro, we used several different metrics.
The primary metric used was the area under the curve
(AUC) of the receiver operating characteristic (ROC). This
metric was preferred because of its ability to measure the
performance of the predictor independent of the threshold
used for classification and it is not dependent on the number
of positive and negative test cases. In addition, AUC was the
metric recommended for benchmarking epitope prediction
performance at a workshop organized by the National
Institute of Allergy and Infectious Disease in 2006
(Greenbaum et al., 2007). Intuitively, the AUC is the prob-
ability that a randomly chosen positive test case will have a
score greater than a randomly chosen negative test case. An
AUC of 1.0 corresponds to a perfect score and an AUC of
0.5 corresponds to a random predictor. In addition, we use
several threshold-dependent metrics including accuracy, sen-
sitivity (also known as recall), specificity, precision and F1
measure (Baldi et al., 2000). The 95% confidence intervals
were determined using 100 000 bootstrap samples.
Results
Performance on the ChenFrag dataset
We first benchmarked COBEpro’s performance on the
ChenFrag dataset. Using the 10-fold cross-validation scheme
as described previously with a linear kernel, we achieved an
AUC of 0.685. The best cross-validated performance was
obtained using a Gaussian kernel with a width of 0.001.
Using these settings, COBEpro achieved an AUC of 0.829
and an accuracy of 78.0%. Additional performance measures
for a variety of kernel widths are given in Table I. The
thresholds used for the various performance measures were
selected to maximize the accuracy on the parameter-tuning
fold. The ROC curves for the ChenFrag dataset as well as
the other fragment datasets are displayed in Fig. 2. It is
worthwhile to note that the ROC curve of the performance
on the ChenFrag dataset is higher than the ROC curve of the
performance on the BCPREDFrag dataset. This is most
likely due to the homologous proteins in the ChenFrag
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dataset and the redundancy reduction performed on the
BCPREDFrag dataset.
Performance on the BCPREDFrag dataset
On the recently curated BCPREDFrag dataset, COBEpro
achieved an AUC (0.768) higher than any previous predictor.
Additional performance measures are recorded in Table II.
As noted previously, the most likely explanation for the dis-
crepancy in AUC performance between the BCPREDFrag
dataset and the ChenFrag dataset is the presence of homo-
logous proteins in the ChenFrag dataset and absence of hom-
ologous proteins in the BCPREDFrag dataset.
Performance on the HIV and Pellequer fragment datasets
We analyzed the performance of COBEpro on the Pellequer
and HIV fragment datasets using the optimal kernel para-
meters found while benchmarking COBEpro on the
ChenFrag dataset. In our analysis, we explore the usage of
either a fixed length or varying length window and the usage
of the amino acid sequence alone or in combination with the
secondary structure and solvent accessibility. The results
from our benchmarking are reported in Tables III and IV.
Without a validation dataset, the threshold for the perform-
ance measures is set to predict the same frequency of epi-
topes in the test dataset (CV threshold).
While the SVMs trained with the PellFragFL and
HIVFragFL datasets failed to achieve an AUC much higher
Fig. 1. Schemes for predicting residue epitopic propensity scores. One scheme for predicting residue epitopic propensity scores could sum the raw SVM
scores for each fragment that covers a residue. Another scheme could use the top 5% most likely fragments as positive votes (top left). Yet another scheme
could use the 5% least likely fragments as negative votes (top right). The optimal scheme for combining the fragment epitopic propensity scores sums the
votes for both the 5% most likely and 5% least likely fragments to produce a residue epitopic propensity score (bottom center).
Table I. Cross-validated performance on the ChenFrag fragment dataset
Linear
kernel
Gaussian kernel, Kðx; zÞ ¼ exp  jjxyjj2
2s2
 
s ¼ 0.01 s ¼ 0.001 s ¼ 0.0001 s ¼ 0.00001
AUC 0.685 0.521 0.829 0.820 0.806
CV Threshold 21.65 20.18 20.03 21.04 21.03
Accuracy (%) 64.7 50.4 78.0 77.4 75.9
Sensitivity (%) 43.6 40.7 60.9 62.4 58.0
Specificity (%) 85.8 60.1 95.1 92.4 93.8
Precision (%) 75.4 50.5 92.5 89.2 90.4
F-measure (%) 55.3 45.1 73.4 73.4 70.7
The cutoff for calculating the threshold-dependent performance measures is
selected to maximize accuracy on the parameter-tuning fold. Bold values
indicate the highest AUC ROC performance.
M.J.Sweredoski and P.Baldi
116
D
ow
nloaded from
 https://academ
ic.oup.com
/peds/article-abstract/22/3/113/1562248 by C
alifornia Institute of Technology user on 21 April 2020
than random, the SVMs trained with the PellFragVL and
HIVFragVL datasets performed significantly better. While
the incorporation of the secondary structure and solvent
accessibility in the PellFragFLstruct and HIVFragFLstruct
datasets did not increase performance, the structural feature
predictions had a positive impact on the PellFragVLstruct
and HIVFragVLstruct datasets; with increases in the AUC of
0.102 and 0.214, respectively, over the datasets not incorpor-
ating secondary structure and relative solvent accessibility.
Using the PellFragVLstruct dataset for training the SVMs,
COBEpro achieved an AUC of 0.632 on the
HIVFragVLstruct dataset. Using the HIVFragVLstruct
dataset for training the SVMs, COBEpro achieved an AUC
of 0.606 on the PellFragVLstruct dataset.
Performance on HIV and Pellequer whole sequence datasets
COBEpro’s residue epitopic propensity performance on the
HIV and Pellequer datasets was benchmarked by alternately
using one dataset for training the SVM and the other for
evaluation. The results from the different prediction schemes
are in Table V. In both datasets, by combining the predic-
tions of the most likely epitope and non-epitope fragments,
COBEpro was able to achieve an AUC of 0.628 with a 95%
confidence interval of (0.559, 0.698) on the Pellequer dataset
and an AUC of 0.605 with a 95% confidence interval of
(0.557, 0.656) on the HIV datasets.
As an example of the performance of COBEpro for
making predictions on whole sequences, we highlight one
protein from the Pellequer dataset, IFB (Fig. 3). COBEpro
was able to achieve an AUC of 0.831 with regard to the
residue epitopic propensity scoring on this sample protein. It
is worthwhile to note that the number of residues with a
positive epitopic propensity score will be roughly equal to
the number of residues with a negative epitopic propensity
scores because of the voting-based prediction scheme. Since
there are typically fewer epitopic residues than non-epitopic
residues, there will inherently be more false positives than
false negatives. This is tolerable since the primary goal of
Table V. Residue epitopic propensity performance (AUC) on Pellequer and
HIV datasets
Test dataset Raw SVM
score
Top 5% Bottom 5% Top and
bottom 5%
PellWholestruct 0.589 0.605 0.603 0.628
HIVWholestruct 0.547 0.588 0.578 0.605
The PellWholestruct dataset was evaluated using an SVM trained on the
HIVFragVLstruct dataset. The HIVWholestruct dataset was evaluated using
an SVM trained on the PellFragVLstruct dataset.
Fig. 2. ROC curves for the fragment datasets. The ChenFrag and
BCPREDFrag datasets contain only fixed length primary sequence fragments
and non-epitope fragments are randomly selected from SWISS-PROT. The
ChenFrag datasets contain homologous proteins, whereas the BCPREDFrag
datasets are redundancy reduced. The PellFragFLstruct and
HIVFragVLstruct datasets contain variable length epitopes fragments with
primary sequence information as well as predicted secondary structure and
solvent accessibility. Both the PellFragFLstruct and HIVFragVLstruct
datasets are redundancy-reduced and non-epitope fragments are drawn from
portions of antigenic sequences not annotated as being in an epitope.
Table II. Cross-validated performance on the BCPREDFrag fragment
dataset
Linear
kernel
Gaussian kernel, Kðx; zÞ ¼ exp  jjxyjj2
2s2
 
s ¼ 0.01 s ¼ 0.001 s ¼ 0.0001 s ¼ 0.00001
AUC 0.592 0.527 0.768 0.727 0.592
Accuracy (%) 56.2 50.0 71.4 71.3 69.1
Sensitivity (%) 35.9 29.5 55.4 47.1 48.8
Specificity (%) 76.5 70.5 87.4 95.6 89.4
Precision (%) 60.4 50.0 81.5 91.1 82.2
F-measure (%) 45.0 37.1 66.0 62.1 60.8
The cutoff for calculating the threshold-dependent performance measures is
selected to maximize accuracy on the parameter-tuning fold. Bold values
indicate the highest AUC ROC performance.
Table III. Performance on Pellequer fragment datasets (trained on HIV
datasets)
PellFragFL PellFragFLstruct PellFragVL PellFragVLstruct
AUC 0.485 0.536 0.504 0.606
Accuracy (%) 72.3 84.0 20.4 82.9
Sensitivity (%) 7.2 12.0 92.7 8.4
Specificity (%) 83.5 91.2 7.9 90.3
Precision (%) 7.1 12.0 14.8 8.1
F-measure (%) 7.1 12.0 25.5 8.2
The cutoff for calculating the threshold-dependent performance measures
was selected to ensure that the same percentage of epitopes was predicted as
in the test dataset. Bold values indicate the highest AUC ROC performance.
Table IV. Performance on HIV fragment datasets (trained on Pellequer
datasets)
HIVFragFL HIVFragFLstruct HIVFragVL HIVFragVLstruct
AUC 0.494 0.558 0.418 0.632
Accuracy (%) 82.9 83.3 29.0 84.0
Sensitivity (%) 12.2 10.7 56.4 18.4
Specificity (%) 90.5 90.8 26.1 90.8
Precision (%) 12.2 10.7 7.6 17.1
F-measure (%) 12.2 10.7 13.4 17.7
The cutoff for calculating the threshold-dependent performance measures
was selected to ensure that the same percentage of epitopes was predicted as
in the test dataset. Bold values indicate the highest AUC ROC performance.
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COBEpro is to assign epitopic propensity scores that rank the
residues from most epitopic to least epitopic, not make a
binary classification. While not all proteins were predicted at
as high a performance level, IFB clearly demonstrates the
power of COBEpro to identify the most likely and least
likely regions of antigenic activity.
Performance at Discotope residue epitopic propensity
scoring
In addition to the continuous B-cell epitope datasets, we also
benchmarked COBEpro on the discontinuous dataset curated
for Discotope (Haste Andersen et al., 2006) and subsequently
used in BEpro (Sweredoski and Baldi, 2008) (formerly
PEPITO). We chose to benchmark COBEpro on this dataset
to attempt to determine whether continuous B-cell predictors
could be used to predict discontinuous B-cell epitopes accu-
rately. On this dataset, COBEpro achieved an average AUC
of 0.591 with a 95% confidence interval of (0.582, 0.601).
This is in contrast to the AUC of 0.726 and 0.754 achieved
by Discotope and BEpro, respectively. While COBEpro’s
AUC is considerably lower than previous predictors, it
should be noted that these predictors are trained on discon-
tinuous epitopes and they take an antigen tertiary structure as
input, in contrast to COBEpro, which is trained only on con-
tinuous epitopes and uses only the antigen primary sequence
as input. COBEpro achieved an average recall of 77.5% with
an average precision of 11.9%.
In Fig. 4, we see the predicted residue epitopic propensity
scores for a typical Discotope protein 1FJ1F, which is a
known Lyme disease antigen. Note that COBEpro was able
to identify the discontinuous epitope even though all the
linear segments within the discontinuous epitope are less
than six residues in length.
Assessing the statistical significance of COBEpro
One way to assess the statistical significance of COBEpro is
to compare it to a random predictor. Several rigorous statisti-
cal tests were performed to determine the significance level
at which COBEpro’s performance is better than a random
predictor’s performance for epitopic propensity prediction at
both the residue level and fragment level. The AUC is the
performance metric used in the statistical tests. In each stat-
istical test, the null hypothesis is that a random predictor per-
forms at least as well as COBEpro and the alternate
hypothesis is that COBEpro performs better than a random
predictor. For the purposes of the statistical tests, a random
predictor is defined as a predictor that outputs a random epi-
topic propensity score from the uniform distribution between
zero and one for any input. Other models for random predic-
tors were considered (such as providing a shuffled sequence
as input to COBEpro); however, they were discarded because
they were not applicable in all of the statistical tests per-
formed or did not make truly random predictions. The
uniform distribution between zero and one is acceptable for
calculating the AUC because the AUC is both scale and shift
invariant. More generally, the AUC is only dependent on the
ordering of the predictions.
Estimating the standard deviation of the performance
and P-value
A bootstrap procedure was used to estimate the standard
deviation of the performance of each predictor and the
P-value of the null hypothesis (Efron and Tibshirani, 1993).
In the estimation of the standard deviation of the perform-
ance of COBEpro (SDPRED), the actual predicted values for
each residue or fragment were used. In the estimation of the
standard deviation of the performance of a random predictor
(SDRND), random predictions were obtained for each residue
or fragment from the distribution as described previously.
The exact number of bootstrap samples in each statistical test
(100 000) was selected because it provides a good balance
between attainable precision and computation time. For the
fragment datasets (including ChenFrag, BCPREDFrag,
HIVFragVLstruct and PellFragVLstruct), bootstrap samples
were created by randomly selecting with replacement
Fig. 4. Residue epitopic propensity score predictions for discotope protein
1FJ1F. The areas filled with diagonal hash marks represent the predicted
propensity scores and the columns denoted by vertical and horizontal hash
marks represent the true epitope locations. While there are several false
positive regions, COBEpro has identified the three major epitopic regions
within the discontinuous epitope with fairly tight bounds.
Fig. 3. Residue epitopic propensity score predictions for pellequer protein
IFB. The areas filled with diagonal hash marks represent the predicted
propensity scores and the columns denoted by vertical and horizontal hash
marks represent the true epitope locations.
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fragments from the datasets. For the whole sequence datasets
(including HIVWholestruct, PellWholestruct and Discotope),
bootstrap samples were created by randomly selecting with
replacement sequences from the datasets. The bootstrap esti-
mate of the P-value is the number of times the random pre-
dictor performed at least as well as COBEpro in the 100 000
bootstrap samples divided by 100 000.
Statistical test results
The results of the statistical tests are provided in Tables VI
and VII. The z-score is defined as
mPRED  mRND=ð
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
SD2PRED þ SD2RND
q
Þ, where mRND ¼ 0.5
and mPRED are the observed performance of COBEpro,
which is an unbiased estimate of the true performance.
Given these statistical results, it is clear that one can safely
reject all the null hypotheses that a random predictor per-
forms as well as COBEpro with confidences ranging from 99
to 99.999%.
Discussion
In comparing the results from COBEpro with other predic-
tors, one concludes that COBEpro is at least as well as all
other predictors on each continuous B-cell epitope dataset.
On the ChenFrag dataset, COBEpro achieved a higher accu-
racy than the accuracy reported by Chen et al. (Chen et al.,
2007) (78.0 versus 73.71). On the BCPREDFrag dataset,
COBEpro achieved a higher AUC than the AUC reported by
El-Manzalawy et al. (El-Manzalawy et al., 2008) (0.768
versus 0.758). On the PellWholestruct and HIVWholestruct
datasets, COBEpro achieved a mean AUC half a percentage
point higher than the mean AUC reported by Larsen et al.
(Larsen et al., 2006) (0.605 versus 0.600). COBEpro also
performed quite well on the discontinuous Discotope epitope
dataset, with a mean AUC of 0.591.
There are several features in COBEpro that are novel to
B-cell epitope prediction. In COBEpro’s first step, one
unique feature is the novel input vector to the SVM.
Whereas most predictors use simple protein property scales
and amino acid compositions for input, COBEpro uses a
vector of similarities to other epitope fragments. While
COBEpro’s SVM input may somewhat obfuscate simple
sequence motifs, we believe that this representation com-
bined with the ability of SVMs to handle high dimensional
data allows COBEpro to identify complex patterns that may
be found in B-cell epitopes. COBEpro’s second step differs
significantly from other approaches in how the fragment epi-
topic propensity scores are used. Most systems simply assign
to the middle residue in the peptide fragment the same epito-
pic propensity score as the fragment. COBEpro considers the
fragment epitopic propensity score equally relative to each
residue in the fragment when calculating the residue epitopic
propensity scores, as there is no reason to believe that the
fragment epitopic propensity score is more relevant to the
middle residue than the outer residues in the peptide
fragment.
One may wonder why fragment epitopic propensity scores
are calculated before residue epitopic propensity scores in a
top-down approach, where fragment predictions are made
before residue predictions, as the reverse, bottom-up
approach might seem more natural. However, the first step of
assigning the fragment epitopic propensity scores can be
viewed as a course grained prediction and the second step of
assigning the residue epitopic propensity scores can be
viewed as a fine grain prediction. It may be possible that this
top-down approach could be applied to other prediction tasks
such as protein secondary structure prediction.
A large discrepancy is seen in Fig. 2 between the AUC on
the datasets derived from the BciPep database (0.8) and
the AUC on the datasets derived from the HIV and Pellequer
databases (0.6). This division corresponds to different
methods used for selecting non-epitope fragments. While
there could be several explanations for this observation, we
hypothesize that the models trained on datasets containing
non-epitope fragments randomly sampled from SWISS-
PROT were actually learning to discern antigen sequences
from non-antigen sequences.
To test this hypothesis, we curate a dataset consisting of the
positive fixed-length epitope fragments from the HIVFragFL
dataset and an equal number of non-epitope fragments ran-
domly selected from SWISS-PROT. When we evaluate the
performance of the SVM using 10-fold cross validation on
this dataset, we record an AUC of 0.919. This performance
level is considerably higher than the chance level AUC of
0.494, we record in our unbiased benchmarking where both
epitope and non-epitope fragments are derived from the same
antigenic sequences. When we perform the same test using
the PellFragFL dataset, we record an AUC of 0.713. Again,
this is much higher than the AUC previously recorded in our
unbiased benchmarking of 0.485.
From these results, we can see considerable differences in
performance between methods for selecting non-epitope
fragments and that selecting non-epitopes randomly from
SWISS-PROT appears to produce biased performance
measures. All the available evidence suggests that predictors
trained on datasets containing non-epitope fragments ran-
domly sampled from SWISS-PROT are, in part, learning to
discern antigen source species from non-antigen source
species and that it is necessary to construct training datasets
using only antigenic sequences to prevent biased models and
biased benchmarking. Considering this, we use the
PellFragVLstruct dataset to train the SVM in the online
version of COBEpro since this dataset contains only
Table VI. Statistical tests of COBEpro on fragment epitopic propensity
scoring
Data set mCOBEpro SDCOBEpro SDRND z-score P-value
ChenFrag 0.829 9.97E203 1.38E202 1.93E þ 01 ,1.E205
BCPREDFrag 0.768 1.27E202 1.54E202 1.34E þ 01 ,1.E205
HIVFragVLstruct 0.632 2.86E202 3.00E202 3.18E þ 00 8.4E204
PellFragVLstruct 0.606 2.57E202 3.34E202 2.52E þ 00 6.01E203
Table VII. Statistical tests of COBEpro on residue epitopic propensity
scoring
Dataset mCOBEpro SDCOBEpro SDRND z-score P-value
HIVWholestruct 0.605 2.53E202 1.58E202 3.52E þ 00 1.9E204
PellWholestruct 0.628 3.54E202 1.22E202 3.39E þ 00 2.6E204
Discotope 0.591 4.72E203 1.37E202 6.26E þ 00 ,1.E205
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antigenic sequences and the dataset contains a larger training
library of antigens than the HIVFragVLstruct dataset.
In conclusion, we have demonstrated how COBEpro can
bridge the two approaches for predicting epitopes. Through
careful and unbiased benchmarking, we have demonstrated
that COBEpro achieves a level of performance at least com-
parable to other methods. COBEpro achieves this high per-
formance by incorporating a unique set of input features,
including protein structural features when available.
Additionally, we provide evidence that non-epitope frag-
ments should be drawn from antigenic sequences to ensure
unbiased measurement of epitope prediction performance.
Access to COBEpro is provided online through the
SCRATCH prediction suite.
COBEpro and BEpro can be used to determine the puta-
tive epitopic regions in antigens identified using new high-
throughput protein chips that can identify antigen proteins in
a variety of pathogens. These high-throughput protein chips,
where all of the proteins from an infectious agent are printed
onto a microarray chip and the chip is probed for antibody
reactivity with each possible antigen, have been previously
described in Davies et al. (Davies et al., 2005) and
Sundaresh et al. (Sundaresh et al., 2006). As a proof of
concept, we ran COBEpro on the antigens recently identified
in the pathogen F. tularensis using high-throughput protein
chips (Sundaresh et al., 2007) and the predicted epitopes are
available in the Supplementary data available at PEDS
online. These predictions are left for future experimental lab-
oratories to confirm. In time, it is hoped that this combi-
nation of high throughput technology for identifying antigens
with computational methods for identifying epitopes, such as
BEpro and COBEpro, may help improve our ability to
develop synthetic peptide vaccines. Additionally, COBEpro
could be used to improve the effectiveness of therapeutic
proteins by identifying epitopes and then testing in silico
which mutations would reduce the immunogenicity of the
epitopic regions. In each of these examples, COBEpro and
BEpro are not relied upon to give a 100% accurate prediction
nor are they used to distinguish antigen from non-antigen.
Rather, they are most effective in combination with labora-
tories using high-throughput technologies. In this setting,
false positives can be tolerated and COBEpro and BEpro can
be used to reduce the search space to a more manageable
size.
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